Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

1. Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association

Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October (...) 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association , MD, MPH, FAHA, Chair , MD, FAHA, Vice Chair , MD, MSc

2019 American Heart Association

2. Thrombolytics for Patients with Acute or Massive Pulmonary Embolisms: Clinical Effectiveness and Guidelines

Thrombolytics for Patients with Acute or Massive Pulmonary Embolisms: Clinical Effectiveness and Guidelines Thrombolytics for Patients with Acute or Massive Pulmonary Embolisms: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Thrombolytics for Patients with Acute or Massive Pulmonary Embolisms: Clinical Effectiveness and Guidelines Thrombolytics for Patients with Acute or Massive Pulmonary Embolisms: Clinical Effectiveness and Guidelines Last updated: August 27 (...) , 2019 Project Number: RB1385-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of thrombolytics for the treatment of adults with acute or emergent massive pulmonary embolism? What are the evidence-based guidelines regarding thrombolytics in managing adult patients with acute or emergent massive pulmonary embolism? Key Message Three systematic reviews with meta-analyses, seven meta-analyses, five randomized

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Diagnosis and Management of Acute Pulmonary Embolism

Diagnosis and Management of Acute Pulmonary Embolism 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article Navigation Article Contents Article Navigation 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Stavros V Konstantinides Chairperson Germany/Greece Corresponding authors: Stavros

Full Text available with Trip Pro

2019 European Society of Cardiology

4. Could the YEARS algorithm be used to exclude pulmonary embolism during pregnancy? Data from the CT-PE-pregnancy study

Could the YEARS algorithm be used to exclude pulmonary embolism during pregnancy? Data from the CT-PE-pregnancy study The recently proposed YEARS algorithm was shown to safely exclude pulmonary embolism (PE) and reduce the use of computed tomography pulmonary angiography (CTPA) among pregnant women with suspected PE. Our aim was to externally validate this finding.We performed a post hoc analysis of a prospective management outcome study for PE diagnosis in pregnant women. PE was diagnosed

2019 EvidenceUpdates

5. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. (PubMed)

Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. To evaluate the association between experience in the management of acute pulmonary embolism, reflected by hospital case volume, and mortality.Multinational population based cohort study using data from the Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) registry between 1 January 2001 and 31 August 2018.353 hospitals in 16 countries.39 257 consecutive patients with confirmed (...) diagnosis of acute symptomatic pulmonary embolism.Pulmonary embolism related mortality within 30 days after diagnosis of the condition.Patients with acute symptomatic pulmonary embolism admitted to high volume hospitals (>40 pulmonary embolisms per year) had a higher burden of comorbidities. A significant inverse association was seen between annual hospital volume and pulmonary embolism related mortality. Admission to hospitals in the highest quarter (that is, >40 pulmonary embolisms per year

Full Text available with Trip Pro

2019 BMJ

6. Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study. (PubMed)

Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study. Pulmonary embolism (PE) is associated with increased risk for ischemic stroke, but the underlying mechanism remains unclear. The authors hypothesized that paradoxical embolism through patent foramen ovale (PFO) should be the main mechanism.To determine the frequency of recent ischemic stroke in patients with symptomatic PE according to whether PFO was detected.Prospective cohort study (...) was more frequent in the PFO group than in the non-PFO group (9 of 42 patients [21.4%] vs. 15 of 273 patients [5.5%]; difference in proportions, 15.9 percentage points [95% CI, 4.7 to 30.7 percentage points]).Because of inconclusive contrast TTE or MRI, 46 patients were excluded from analysis.Frequency of recent ischemic stroke in patients with symptomatic PE was higher in patients with PFO than in those without PFO. This finding supports the hypothesis that paradoxical embolism is an important

2019 Annals of Internal Medicine

7. Tofacitinib (Xeljanz): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing

Tofacitinib (Xeljanz): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing Following (...) observation in a clinical study of an increased risk of pulmonary embolism and overall mortality with tofacitinib 10 mg twice-daily in rheumatoid arthritis, a safety review has started and new contraindications introduced. The 10 mg twice-daily dose of tofacitinib (authorised for ulcerative colitis) must not be used in patients at high risk of pulmonary embolism. Published 17 May 2019 From: Therapeutic area: , , , A European safety review of tofacitinib ( ) has begun following results from an ongoing

2019 MHRA Drug Safety Update

8. A novel electrocardiographic parameter for diagnosis of acute pulmonary embolism: RS time: RS time in acute pulmonary embolism

A novel electrocardiographic parameter for diagnosis of acute pulmonary embolism: RS time: RS time in acute pulmonary embolism Pulmonary embolism (PE) is one of the leading causes of cardiovascular mortality worldwide. Electrocardiography (ECG) may provide useful information for patients with acute PE. In this study, we aimed to investigate the diagnostic value of the QRS duration and RS time in inferolateral leads in patients admitted to the emergency department, and pre-diagnosed with acute (...) PE.We retrospectively enrolled 136 consecutive patients, admitted to the emergency department, pre-diagnosed with the clinical suspicion of acute PE, and underwent computerized tomographic pulmonary angiography (CTPA) to confirm the PE diagnosis. The study subjects were divided into two groups according to the presence or absence of PE, and the independent predictors of PE were investigated.Sixty-eight patients (50%) had PE. Patients with PE had a longer RS time. Among the ECG parameters, only RS

2019 EvidenceUpdates

9. Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. (PubMed)

Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. Pulmonary embolism is one of the leading causes of maternal death in the Western world. Because of the low specificity and sensitivity of the d-dimer test, all pregnant women with suspected pulmonary embolism undergo computed tomographic (CT) pulmonary angiography or ventilation-perfusion scanning, both of which involve radiation exposure to the mother and fetus. Whether a pregnancy-adapted algorithm could be used (...) to safely avoid diagnostic imaging in pregnant women with suspected pulmonary embolism is unknown.In a prospective study involving pregnant women with suspected pulmonary embolism, we assessed three criteria from the YEARS algorithm (clinical signs of deep-vein thrombosis, hemoptysis, and pulmonary embolism as the most likely diagnosis) and measured the d-dimer level. Pulmonary embolism was ruled out if none of the three criteria were met and the d-dimer level was less than 1000 ng per milliliter

Full Text available with Trip Pro

2019 NEJM

10. Outpatient versus inpatient treatment for acute pulmonary embolism. (PubMed)

Outpatient versus inpatient treatment for acute pulmonary embolism. Pulmonary embolism (PE) is a common life-threatening cardiovascular condition, with an incidence of 23 to 69 new cases per 100,000 people each year. For selected low-risk patients with acute PE, outpatient treatment might provide several advantages over traditional inpatient treatment, such as reduction of hospitalisations, substantial cost savings, and improvements in health-related quality of life. This is an update

2019 Cochrane

11. The Prognostic Value of Renal Function in Acute Pulmonary Embolism-A Multi-Centre Cohort Study

The Prognostic Value of Renal Function in Acute Pulmonary Embolism-A Multi-Centre Cohort Study  Haemodynamic alterations caused by acute pulmonary embolism (PE) may affect multi-organ function including kidneys. This multi-centre, multinational cohort study aimed to validate the prognostic significance of estimated glomerular filtration rate (eGFR) and its potential additive value to the current PE risk assessment algorithms. The post hoc analysis of pooled prospective cohort studies: 2,845

2019 EvidenceUpdates

12. Rapid blood test helps exclude pulmonary embolism for low risk patients

Rapid blood test helps exclude pulmonary embolism for low risk patients Rapid blood test helps exclude pulmonary embolism for low risk patients Discover Portal Discover Portal Rapid blood test helps exclude pulmonary embolism for low risk patients Published on 25 October 2016 doi: An inexpensive blood test can help quickly rule out pulmonary embolism for low risk patients attending hospital outpatient or emergency departments, especially in people with early symptoms. This review looked (...) diagnostic imaging. Overall a change in the management pathway for suspected pulmonary embolism (PE) have potential to be cost saving and provide better care. Commissioners, will be interested in the overall pathway costs but unfortunately these were not researched here. Share your views on the research. Why was this study needed? In the UK, 47,734 cases of PE were reported between 2014 and 2015. Emergency admissions for PE increased by 30% between 2008 and 2012. A pulmonary embolism is a blockage

2019 NIHR Dissemination Centre

13. Diagnostic accuracy of dual-energy CT in detection of acute pulmonary embolism: a systematic review and meta-analysis

Diagnostic accuracy of dual-energy CT in detection of acute pulmonary embolism: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

14. Venoarterial-extracorporeal membrane oxygenation for life-threatening massive pulmonary embolism - a systematic review on predictors of mortality

Venoarterial-extracorporeal membrane oxygenation for life-threatening massive pulmonary embolism - a systematic review on predictors of mortality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

15. Systematic review to assess the effectiveness and safety of extra-corporeal life support in patients with complicated pulmonary embolism

Systematic review to assess the effectiveness and safety of extra-corporeal life support in patients with complicated pulmonary embolism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

16. Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in patients with pulmonary embolism: a systematic review and meta-analysis

Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in patients with pulmonary embolism: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

17. The clinical net benefit of thrombolysis in the management of submassive pulmonary embolism: systematic review and meta-analysis

The clinical net benefit of thrombolysis in the management of submassive pulmonary embolism: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

18. Prognostic value of RV/LV ratio on computed tomography pulmonary angiography in patients with pulmonary embolism: a systematic review and meta-analysis

Prognostic value of RV/LV ratio on computed tomography pulmonary angiography in patients with pulmonary embolism: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

19. The prognostic value of right ventricular function assessed by echocardiographic measurements in acute pulmonary embolism: a systematic review and meta-analysis

The prognostic value of right ventricular function assessed by echocardiographic measurements in acute pulmonary embolism: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

20. Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial. (PubMed)

Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial. To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in acute PE.This was a randomized, placebo-controlled, double blind trial conducted at four academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus

2019 Nitric oxide : biology and chemistry Controlled trial quality: predicted high